1. Home
  2. SGLY vs INDP Comparison

SGLY vs INDP Comparison

Compare SGLY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Singularity Future Technology Ltd.

SGLY

Singularity Future Technology Ltd.

HOLD

Current Price

$6.30

Market Cap

3.4M

Sector

N/A

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.20

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGLY
INDP
Founded
2001
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
171.9M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
SGLY
INDP
Price
$6.30
$1.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
300.2K
91.2K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
48.29
N/A
EPS
N/A
N/A
Revenue
$1,813,193.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.92
52 Week High
$8.65
$8.57

Technical Indicators

Market Signals
Indicator
SGLY
INDP
Relative Strength Index (RSI) 67.64 29.95
Support Level $0.38 $0.92
Resistance Level N/A $3.05
Average True Range (ATR) 1.12 0.24
MACD 0.35 -0.06
Stochastic Oscillator 70.46 2.80

Price Performance

Historical Comparison
SGLY
INDP

About SGLY Singularity Future Technology Ltd.

Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: